nChromaBio

nChroma Bio was formed in December 2024 through the merger of Chroma Medicine and Nvelop Therapeutics. nChroma Bio aims to redefine genetic medicine by combining Chroma's expertise in epigenetic editing with Nvelop's advancements in non-viral, programmable delivery systems. The company's lead program, CRMA-1001, is a liver-targeted epigenetic therapy designed as a potential functional cure for chronic hepatitis B and D. Unlike traditional gene editing methods that cut DNA, CRMA-1001 modulates gene expression without altering the DNA sequence, thereby reducing the risk of unintended genomic changes.